Serum pro-inflammatory biomarkers associated with improvement in quality of life in pulmonary tuberculosis

Front Immunol. 2023 Sep 11:14:1241121. doi: 10.3389/fimmu.2023.1241121. eCollection 2023.

Abstract

Introduction: Pulmonary dysfunction is an underestimated complication in tuberculosis (TB) infection, affecting quality of life (QoL). Although respiratory function tests objectively reflect lung disturbances in a specific moment, predictors of illness severity at the time of diagnosis are still lacking.

Methods: We measured serum pro-inflammatory cytokines (TNF-α and IL-8), eicosanoids (PGE2, LTB4, RvD1, Mar1, and LXA4), a marker of tissue damage (cell-free nucleosomes), and indicators of redox status (malonaldehyde, 8-isoprostane, total oxidants, and antioxidants), as well as a score of radiological abnormalities (SRA) and a QoL questionnaire, in 25 patients with pulmonary TB at the time of diagnosis (t0) and two months after the initiation of treatment (t2).

Results: We found higher antioxidant levels in the patients with the worst QoL at t0, and all the indicators of the prooxidant state were significantly reduced at t2, while the total antioxidant levels increased. LTB4, a pro-inflammatory eicosanoid, was diminished at t2, while all the pro-resolutory lipids decreased substantially. Significant correlations between the SRA and the QoL scores were observed, the latter showing a substantial reduction at t2, ranking it as a reliable tool for monitoring disease evolution during TB treatment.

Discussion: These results suggest that evaluating a combination of these markers might be a valuable predictor of QoL improvement and a treatment response indicator; in particular, the oxidation metabolites and eicosanoid ratios could also be proposed as a future target for adjuvant therapies to reduce inflammation-associated lung injury in TB disease.

Keywords: eicosanoids; inflammation-associated lung injury; quality of life; redox indicators; tuberculosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antioxidants
  • Cognition
  • Humans
  • Latent Tuberculosis*
  • Leukotriene B4
  • Quality of Life
  • Tuberculosis, Pulmonary* / drug therapy

Substances

  • Antioxidants
  • Leukotriene B4

Grants and funding

This study received funding from the Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT, Mexico), grant number A3-S-35173. The funder had no role in data design, performance, and interpretation.